Hepatitis B vaccine development and implementation

References

• Blumberg BS, Alter HJ, Visnich S. A “new” antigen in leukemia sera. JAMA. 1965;191(7):541–46. doi:10.1001/jama.1965.03080070025007.
   PubMed Web of Science ®Google Scholar
• Dane DS, Cameron CH, Briggs M. Virus-like particles in serum of patients with Australia-antigen-associated hepatitis. Lancet. 1970;1(7649):695–98. doi:10.1016/s0140-6736(70)90926-8.
   PubMed Web of Science ®Google Scholar
• Krugman S, Giles JP, Hammond J. Hepatitis virus: effect of heat on the infectivity and antigenicity of the MS-1 and MS-2 strains. J Infect Dis. 1970;122(5):432–36. doi:10.1093/infdis/122.5.432.
   PubMed Web of Science ®Google Scholar
• Krugman S, Giles JP, Hammond J. Viral hepatitis, type B (MS-2 strain). Studies on active immunization. JAMA. 1971;217(1):41–45. doi:10.1001/jama.1971.03190010023005.
   PubMed Web of Science ®Google Scholar
• Krugman S, Giles JP, Hammond J. Viral hepatitis, type B (MS-2 strain) prevention with specific hepatitis B immune serum globulin. JAMA. 1971;218(11):1665–70. doi:10.1001/jama.1971.03190240019005.
   PubMed Web of Science ®Google Scholar
• Hollinger FB, Liang JK. Hepatitis B virus. In: Knipe D, Howley P, Griffin D editors. Fields virology. 4th. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 2971–3036.
   Google Scholar
• Maynard JE, Berquist KR, Krushak DH, Purcell RH. Experimental infection of chimpanzees with the virus of hepatitis B. Nature. 1972;237(5357):514–15. doi:10.1038/237514a0.
   PubMed Web of Science ®Google Scholar
• Gerin JL, Holland PV, Purcell RH. Australia antigen: large-scale purification from human serum and biochemical studies of its proteins. J Virol. 1971;7(5): 569–76. doi:10.1128/JVI.7.5.569-576.1971.
   PubMed Web of Science ®Google Scholar
• Hilleman MR, Buynak EB, Roehm RR, Tytell AA, Bertland AU, Lampson GP. Purified and inactivated human hepatitis B vaccine: progress report. Am J Med Sci. 1975;270(2):401–04. doi:10.1097/00000441-197509000-00025.
   PubMed Web of Science ®Google Scholar
• Buynak EB, Roehm RR, Tytell AA, Bertland AU 2nd, Lampson GP, Hilleman MR. Development and chimpanzee testing of a vaccine against human hepatitis B. Proc Soc Exp Biol Med. 1976;151(4):694–700. doi:10.3181/00379727-151-39288.
   PubMed Web of Science ®Google Scholar
• Hilleman MR, McAleer WJ, Buynak EB, McLean AA. The preparation and safety of hepatitis B vaccine. J Infect. 1983;7(Suppl 1):3–8. doi:10.1016/s0163-4453(83)96465-4.
   PubMedGoogle Scholar
• Szmuness W, Stevens CE, Harley EJ, Zang EA, Oleszko WR, William DC, Sadovsky R, Morrison JM, Kellner A. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med. 1980;303(15):833–41. doi:10.1056/NEJM198010093031501.
   PubMed Web of Science ®Google Scholar
• Stevens CE, Szmuness W, Goodman AI, Weseley SA, Fotino M. Hepatitis B vaccine: immune responses in haemodialysis patients. Lancet. 1980;2(8206):1211–13. doi:10.1016/s0140-6736(80)92477-0.
   PubMed Web of Science ®Google Scholar
• Maupas P, Chiron JP, Barin F, Coursaget P, Goudeau A, Perrin J, Denis F, Mar ID. Efficacy of hepatitis B vaccine in prevention of early HBsAg carrier state in children. Controlled trial in an endemic area (Senegal). Lancet. 1981;1(8215):289–92. doi:10.1016/s0140-6736(81)91908-5.
   PubMed Web of Science ®Google Scholar
• Krugman S. The newly licensed hepatitis B vaccine. Characteristics and indications for use. JAMA. 1982;247(14):2012–15. doi:10.1001/jama.1982.03320390074052.
   PubMed Web of Science ®Google Scholar
• Goudeau A, Dubois F, Barin F, Dubois MC, Coursaget P. Hepatitis B vaccine: clinical trials in high-risk settings in France. (September 1975–September 1982). Dev Biol Stand. 1983;54: 267–84.
   PubMedGoogle Scholar
• Szmuness W, Stevens CE, Harley EJ, Zang EA, Alter HJ, Taylor PE, DeVera A, Chen GT, Kellner A. Hepatitis B vaccine in medical staff of hemodialysis units: efficacy and subtype cross-protection. N Engl J Med. 1982;307(24):1481–86. doi:10.1056/NEJM198212093072403.
   PubMed Web of Science ®Google Scholar
• Burrell CJ, Mackay P, Greenaway PJ, Hofschneider PH, Murray K. Expression in Escherichia coli of hepatitis B virus DNA sequences cloned in plasmid pBR322. Nature. 1979;279(5708):43–47. doi:10.1038/279043a0.
   PubMed Web of Science ®Google Scholar
• Valenzuela P, Gray P, Quiroga M, Zaldivar J, Goodman HM, Rutter WJ. Nucleotide sequence of the gene coding for the major protein of hepatitis B virus surface antigen. Nature. 1979;280(5725):815–19. doi:10.1038/280815a0.
   PubMed Web of Science ®Google Scholar
• Valenzuela P, Medina A, Rutter WJ, Ammerer G, Hall BD. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature. 1982;298(5872):347–50. doi:10.1038/298347a0.
   PubMed Web of Science ®Google Scholar
• McAleer WJ, Buynak EB, Maigetter RZ, Wampler DE, Miller WJ, Hilleman MR. Human hepatitis B vaccine from recombinant yeast. Nature. 1984;307(5947):178–80. doi:10.1038/307178a0.
   PubMed Web of Science ®Google Scholar
• Scolnick EM, McLean AA, West DJ, McAleer WJ, Miller WJ, Buynak EB. Clinical evaluation in healthy adults of a hepatitis B vaccine made by recombinant DNA. JAMA. 1984;251(21):2812–15. doi:10.1001/jama.1984.03340450028021.
   PubMed Web of Science ®Google Scholar
• Jilg W, Lorbeer B, Schmidt M, Wilske B, Zoulek G, Deinhardt F. Clinical evaluation of a recombinant hepatitis B vaccine. Lancet. 1984;2(8413):1174–75. doi:10.1016/s0140-6736(84)92740-5.
   PubMed Web of Science ®Google Scholar
• Davidson M, Krugman S. Immunogenicity of recombinant yeast hepatitis B vaccine. Lancet. 1985;1(8420):108–09. doi:10.1016/s0140-6736(85)92000-8.
   PubMed Web of Science ®Google Scholar
• Brown SE, Stanley C, Howard CR, Zuckerman AJ, Steward MW. Antibody responses to recombinant and plasma derived hepatitis B vaccines. Br Med J. 1986;292(6514):159–61. doi:10.1136/bmj.292.6514.159.
   PubMedGoogle Scholar
• Yeoh EK, Chang WK, Ip P, Chan KH, Chan E, Fung C. Efficacy and safety of recombinant hepatitis B vaccine in infants born to HBsAg-positive mothers. J Infect. 1986;13(SupplA):15–18. doi:10.1016/s0163-4453(86)92608-3.
   PubMedGoogle Scholar
• Stevens CE, Taylor PE, Tong MJ, Toy PT, Vyas GN, Nair PV, Weissman JY, Krugman S. Yeast-recombinant hepatitis B vaccine. Efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission. JAMA. 1987;257(19):2612–16. doi:10.1001/jama.257.19.2612.
   PubMed Web of Science ®Google Scholar
• Zhou YH, Wu C, Zhuang H. Vaccination against hepatitis B: the Chinese experience. Chin Med J. 2009;122(1):98–102. doi:10.3760/cma.j.issn.0366-6999.2009.01.018.
   PubMed Web of Science ®Google Scholar
• No authors listed. A two-dose hepatitis B vaccine for adults (Heplisav-B). JAMA. 2018;319(8): 822–23. doi:10.1001/jama.2018.1097.
   PubMed Web of Science ®Google Scholar
• Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol. 2002;20: 709–60. doi:10.1146/annurev.immunol.20.100301.064842.
   PubMed Web of Science ®Google Scholar
• Sablan BP, Kim DJ, Barzaga NG, Chow WC, Cho M, Ahn SH, Hwang SG, Lee JH, Namini H, Heyward WL. Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine. Vaccine. 2012;30(16):2689–96. doi:10.1016/j.vaccine.2012.02.001.
   PubMed Web of Science ®Google Scholar
• Heyward WL, Kyle M, Blumenau J, Davis M, Reisinger K, Kabongo ML, Bennett S, Janssen RS, Namini H, Martin JT. Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40–70 years of age. Vaccine. 2013;31(46):5300–05. doi:10.1016/j.vaccine.2013.05.068.
   PubMed Web of Science ®Google Scholar
• Janssen JM, Jackson S, Heyward WL, Janssen RS. Immunogenicity of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in subpopulations of healthy adults 18–70 years of age. Vaccine. 2015;33(31):3614–18. doi:10.1016/j.vaccine.2015.05.070.
   PubMed Web of Science ®Google Scholar
• Janssen RS, Mangoo-Karim R, Pergola PE, Girndt M, Namini H, Rahman S, Bennett SR, Heyward WL, Martin JT. Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease. Vaccine. 2013;31(46):5306–13. doi:10.1016/j.vaccine.2013.05.067.
   PubMed Web of Science ®Google Scholar
• Janssen JM, Heyward WL, Martin JT, Janssen RS. Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease and type 2 diabetes mellitus. Vaccine. 2015;33(7):833–37. doi:10.1016/j.vaccine.2014.12.060.
   PubMed Web of Science ®Google Scholar
• Hyer R, McGuire DK, Xing B, Jackson S, Janssen R. Safety of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant in adults. Vaccine. 2018;36(19):2604–11. doi:10.1016/j.vaccine.2018.03.067.
   PubMed Web of Science ®Google Scholar
• Martin P, Dubois C, Jacquier E, Dion S, Mancini-Bourgine M, Godon O, Kratzer R, Lelu-Santolaria K, Evlachev A, Meritet JF, et al. TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice. Gut. 2015;64(12): 1961–71. doi:10.1136/gutjnl-2014-308041.
   PubMed Web of Science ®Google Scholar
• Whitacre DC, Peters CJ, Sureau C, Nio K, Li F, Su L, Jones JE, Isogawa M, Sallberg M, Frelin L, et al. Designing a therapeutic hepatitis B vaccine to circumvent immune tolerance. Hum Vaccin Immunother. 2019. Epub ahead of print. doi:10.1080/21645515.2019.1689745.
   PubMed Web of Science ®Google Scholar
• Gehring AJ, Protzer U. Targeting innate and adaptive immune responses to cure chronic HBV infection. Gastroenterol. 2019;156(2):325–37. doi:10.1053/j.gastro.2018.10.032.
   PubMed Web of Science ®Google Scholar
• Fanning GC, Zoulim F, Hou J, Bertoletti A. Therapeutic strategies for hepatitis B virus infection: towards a cure. Nat Rev Drug Discov. 2019;18(11):827–44. doi:10.1038/s41573-019-0037-0.
   PubMed Web of Science ®Google Scholar
• Mancini-Bourgine M, Fontaine H, Scott-Algara D, Pol S, Bréchot C, Michel ML. Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers. Hepatology. 2004;40(4):874–82. doi:10.1002/hep.20408.
   PubMed Web of Science ®Google Scholar
• Michel ML, Deng Q, Mancini-Bourgine M. Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges. J Hepatol. 2011;54(6):1286–96. doi:10.1016/j.jhep.2010.12.031.
   PubMed Web of Science ®Google Scholar
• Wong VC, Ip HM, Reesink HW, Lelie PN, Reerink-Brongers EE, Yeung CY, Ma HK. Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis-B vaccine and hepatitis-B immunoglobulin. double-blind randomised placebo-controlled study. Lancet. 1984;1(8383):921–26. doi:10.1016/s0140-6736(84)92388-2.
   PubMed Web of Science ®Google Scholar
• Moyes CD, Milne A, Dimitrakakis M, Goldwater PN, Pearce N. Very-low-dose hepatitis B vaccine in newborn infants: an economic option for control in endemic areas. Lancet. 1987;1(8523):29–31. doi:10.1016/s0140-6736(87)90712-4.
   PubMed Web of Science ®Google Scholar
• Kane M. Reduced doses of hepatitis B vaccines: is it a good idea? Bull World Health Organ. 1995;73:529–30.
   PubMed Web of Science ®Google Scholar
• Poland GA, Jacobson RM. Clinical practice: prevention of hepatitis B with the hepatitis B vaccine. N Engl J Med. 2004;351(27):2832–38. doi:10.1056/NEJMcp041507.
   PubMed Web of Science ®Google Scholar
• Liu F, Guo Z, Dong C. Influences of obesity on the immunogenicity of hepatitis B vaccine. Hum Vaccin Immunother. 2017;13(5):1014–17. doi:10.1080/21645515.2016.1274475.
   PubMed Web of Science ®Google Scholar
• Abara WE, Qaseem A, Schillie S, McMahon BJ, Harris AM. High value care task force of the American college of physicians and the centers for disease control and prevention. Hepatitis B vaccination, screening, and linkage to care: best practice advice from the American college of physicians and the centers for disease control and prevention. Ann Intern Med. 2017;167(11):794–804. doi:10.7326/M17-1106.
   PubMed Web of Science ®Google Scholar
• WHO. Immunization coverage. Fact sheet. Updated 2019 Jul 15. http://www.who.int/mediacentre/factsheets/fs378/en/.
   Google Scholar
• Syed YY. DTaP-IPV-HepB-Hib vaccine (Hexyon®): an updated review of its use in primary and booster vaccination. Paediatr Drugs. 2019;21(5):397–408. doi:10.1007/s40272-019-00353-7.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Xu J, Johnson DR, Hall J, Marček T, Goveia MG, Acosta CJ, Lee AW. Hepatitis B and pertussis antibodies in 4- to 5-year-old children previously vaccinated with different hexavalent vaccines. Hum Vaccin Immunother. 2019; 1–8. Epub ahead of print. doi:10.1080/21645515.2019.1673119.
   PubMed Web of Science ®Google Scholar
• Kosalaraksa P, Chokephaibulkit K, Benjaponpitak S, Pancharoen C, Chuenkitmongkol S, B’Chir S, Da Costa X, Vidor E. Persistence of hepatitis B immune memory until 9–10 years of age following hepatitis B vaccination at birth and DTaP-IPV-HB-PRP~T vaccination at 2, 4 and 6 months. Hum Vaccin Immunother. 2018;14(5):1257–65. doi:10.1080/21645515.2018.1426418.
   PubMed Web of Science ®Google Scholar
• Khan J, Shil A, Mohanty SK. Hepatitis B vaccination coverage across India: exploring the spatial heterogeneity and contextual determinants. BMC Public Health. 2019;19(1):1263. doi:10.1186/s12889-019-7534-2.
   PubMed Web of Science ®Google Scholar
• Insulander M, Lindh G, Stenkvist J, Samuelson A, Fischler B. Long-term follow-up of a vaccination program for infants born to HBsAg-positive mothers in Stockholm county, Sweden. Vaccine. 2020;38(4):790–93. doi:10.1016/j.vaccine.2019.10.100.
   PubMed Web of Science ®Google Scholar
• Zahradnik JM, Heiberg D, Hollinger FB. Hepatitis B vaccine: immune responses in children from families with an HBsAg carrier. Vaccine. 1985;3(5):407–13. doi:10.1016/0264-410x(85)90132-x.
   PubMed Web of Science ®Google Scholar
• Hu Y, Wu Q, Xu B, Zhou Z, Wang Z, Zhou YH. Influence of maternal antibody against hepatitis B surface antigen on active immune response to hepatitis B vaccine in infants. Vaccine. 2008;26(48):6064–67. doi:10.1016/j.vaccine.2008.09.014.
   PubMed Web of Science ®Google Scholar
• Giammanco G, Li Volti S, Mauro L, Bilancia GG, Salemi I, Barone P, Musumeci S. Immune response to simultaneous administration of a recombinant DNA hepatitis B vaccine and multiple compulsory vaccines in infancy. Vaccine. 1991;9(10):747–50. doi:10.1016/0264-410x(91)90291-d.
   PubMed Web of Science ®Google Scholar
• Belloni C, Orsolini P, Martinetti M, Chirico G, Cerbo RM, Comolli G, Maccarini U, Barlassina C, Togni C, Polatti F, et al. Control of hepatitis B: evaluation of two different vaccinal schedules in newborns from HBsAg negative mothers. New Microbiol. 1993;16(3): 237–44.
   PubMedGoogle Scholar
• Perrin J, Coursaget P, Ntareme F, Chiron JP. Hepatitis B immunization of newborns according to a two dose protocol. Vaccine. 1986;4(4):241–44. doi:10.1016/0264-410x(86)90137-4.
   PubMed Web of Science ®Google Scholar
• Huang H, Ning M, Liu J, Chen J, Feng J, Dai Y, Hu Y, Zhou YH. Comparison of antibody response to hepatitis B vaccination in infants with positive or negative maternal hepatitis B e antigen (HBeAg) in cord blood: implication for the role of HBeAg as an immunotolerogen. Hum Vaccin Immunother. 2019;15(9):2183–86. doi:10.1080/21645515.2019.1575712.
   PubMed Web of Science ®Google Scholar
• Van Den Ende C, Marano C, Van Ahee A, Bunge EM, De Moerlooze L. The immunogenicity and safety of GSK’s recombinant hepatitis B vaccine in adults: a systematic review of 30 years of experience. Expert Rev Vaccines. 2017;16(8):811–32. doi:10.1080/14760584.2017.1338568.
   PubMed Web of Science ®Google Scholar
• Bruce MG, Bruden D, Hurlburt D, Zanis C, Thompson G, Rea L, Toomey M, Townshend-Bulson L, Rudolph K, Bulkow L, et al. Antibody levels and protection after hepatitis B vaccine: results of a 30-year follow-up study and response to a booster dose. J Infect Dis. 2016;214(1): 16–22. doi:10.1093/infdis/jiv748.
   PubMed Web of Science ®Google Scholar
• Osiowy C. From infancy and beyond … ensuring a lifetime of hepatitis B virus (HBV) vaccine-induced immunity. Hum Vaccin Immunother. 2018;14(8):2093–97. doi:10.1080/21645515.2018.1462428.
   PubMed Web of Science ®Google Scholar
• Bini C, Grazzini M, Chellini M, Mucci N, Arcangeli G, Tiscione E, Bonanni P. Is hepatitis B vaccination performed at infant and adolescent age able to provide long-term immunological memory? An observational study on healthcare students and workers in Florence, Italy. Hum Vaccin Immunother. 2018;14(2):450–55. doi:10.1080/21645515.2017.1398297.
   PubMed Web of Science ®Google Scholar
• Zhao H, Zhou YH. Revaccination against hepatitis B in late teenagers who received vaccination during infancy: yes or no? Hum Vaccin Immunother. 2018;14(2):456–63. doi:10.1080/21645515.2017.1397243.
   PubMed Web of Science ®Google Scholar
• Haber P, Moro PL, Ng C, Lewis PW, Hibbs B, Schillie SF, Nelson NP, Li R, Stewart B, Cano MV. Safety of currently licensed hepatitis B surface antigen vaccines in the United States, Vaccine Adverse Event Reporting System (VAERS), 2005–2015. Vaccine. 2018;36(4):559–64. doi:10.1016/j.vaccine.2017.11.079.
   PubMed Web of Science ®Google Scholar
• Moro PL, Zheteyeva Y, Barash F, Lewis P, Cano M. Assessing the safety of hepatitis B vaccination during pregnancy in the Vaccine Adverse Event Reporting System (VAERS), 1990–2016. Vaccine. 2018;36(1):50–54. doi:10.1016/j.vaccine.2017.11.039.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Update: vaccine side effects, adverse reactions and precautions. Recommendations of the advisory committee on immunization practices. MMWR. 1996;45(RR–12): 1–35.
   PubMedGoogle Scholar
• Lewis E, Shinefield HR, Woodruff BA, Black SB, Destefano F, Chen RT, Ensor R. Vaccine safety datalink workgroup. Safety of neonatal hepatitis B vaccine administration. Pediatr Infect Dis J. 2001;20(11):1049–54. doi:10.1097/00006454-200111000-00009.
   PubMed Web of Science ®Google Scholar
• Eriksen EM, Perlman JA, Miller A, Marcy SM, Lee H, Vadheim C, Zangwill KM, Chen RT, DeStefano F, Lewis E, et al. Lack of association between hepatitis B birth immunization and neonatal death: a population-based study from the vaccine safety datalink project. Pediatr Infect Dis J. 2004;23(7): 656–62. doi:10.1097/01.inf.0000130953.08946.d0.
   PubMed Web of Science ®Google Scholar
• Mouchet J, Salvo F, Raschi E, Poluzzi E, Antonazzo IC, De Ponti F, Bégaud B. Hepatitis B vaccination and the putative risk of central demyelinating diseases -a systematic review and meta-analysis. Vaccine. 2018;36(12):1548–55. doi:10.1016/j.vaccine.2018.02.036.
   PubMed Web of Science ®Google Scholar
• Stahl JP, Denis F, Gaudelus J, Cohen R, Lepetit H, Martinot A. Hepatitis B vaccination and adolescents: a lost generation. Med Mal Infect. 2016;46(1):1–3. doi:10.1016/j.medmal.2015.11.002.
   PubMed Web of Science ®Google Scholar
• Yue C, Sun X, Wei N, Yu W, Cui F, Wang H, Li L, Zhang L, Shi G, An Z. Quick assessment of the influence of the hepatitis B vaccine event on children’s vaccination. Hum Vaccin Immunother. 2016;12(10):2611–15. doi:10.1080/21645515.2016.1187351.
   PubMed Web of Science ®Google Scholar
• Li X, Dumolard L, Patel M, Gacic-Dobo M, Hennessey K. Implementation of hepatitis B birth dose vaccination–worldwide, 2016. Wkly Epidemiol Rec. 2018;93(7): 61–72.
   PubMedGoogle Scholar
• Alter MJ. Epidemiology and prevention of hepatitis B. Semin Liver Dis. 2003;23(1):39–46. doi:10.1055/s-2003-37583.
   PubMed Web of Science ®Google Scholar
• Ujiie M, Sasaki K, Yoshikawa N, Enami T, Shobayashi T. Introduction of a hepatitis B vaccine into the national routine immunisation programme of Japan. Lancet Infect Dis. 2016;16(12):1325. doi:10.1016/S1473-3099(16)30463-7.
   PubMed Web of Science ®Google Scholar
• Torjesen I. UK adds hepatitis B to infant vaccination schedule. BMJ. 2017;358: j3357. doi:10.1136/bmj.j3357.
   PubMedGoogle Scholar
• Mandal S. Introduction of universal infant hepatitis B immunisation in the UK- paving the way to elimination. Hum Vaccin Immunother. 2019;15(2):440–43. doi:10.1080/21645515.2018.1528837.
   PubMed Web of Science ®Google Scholar
• Maurice J. First countries to be recipients of GAVI funds. Bull World Health Organ. 2000;78:1477–78.
   PubMed Web of Science ®Google Scholar
• Lee LA, Franzel L, Atwell J, Datta SD, Friberg IK, Goldie SJ, Reef SE, Schwalbe N, Simons E, Strebel PM, et al. The estimated mortality impact of vaccinations forecast to be administered during 2011–2020 in 73 countries supported by the GAVI Alliance. Vaccine. 2013;31(Suppl 2): B61–72. doi:10.1016/j.vaccine.2012.11.035.
   PubMed Web of Science ®Google Scholar
• WHO. Global Hepatitis Report. 2017. https://www.who.int/hepatitis/publications/global-hepatitis-report2017-executive-summary/en/.
   Google Scholar
• Sun KX, Li J, Zhu FC, Liu JX, Li RC, Zhai XJ, Li YP, Chang ZJ, Nie JJ, Zhuang H. A predictive value of quantitative HBsAg for serum HBV DNA level among HBeAg-positive pregnant women. Vaccine. 2012;30(36):5335–40. doi:10.1016/j.vaccine.2012.06.036.
   PubMed Web of Science ®Google Scholar
• Wen WH, Chang MH, Zhao LL, Ni YH, Hsu HY, Wu JF, Chen PJ, Chen DS, Chen HL. Mother-to-infant transmission of hepatitis B virus infection: significance of maternal viral load and strategies for intervention. J Hepatol. 2013;59(1):24–30. doi:10.1016/j.jhep.2013.02.015.
   PubMed Web of Science ®Google Scholar
• Liu J, Bi Y, Xu C, Liu L, Xu B, Chen T, Chen J, Pan M, Hu Y, Zhou YH. Kinetic changes of viremia and viral antigens of hepatitis B virus during and after pregnancy. Medicine. 2015;94(45):e2001. doi:10.1097/MD.0000000000002001.
   PubMed Web of Science ®Google Scholar
• Mast EE, Margolis HS, Fiore AE, Brink EW, Goldstein ST, Wang SA, Moyer LA, Bell BP, Alter MJ. Advisory Committee on Immunization Practices (ACIP). A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep. 2005;54:1–31.
   PubMedGoogle Scholar
• Oon CJ, Lim GK, Ye Z, Goh KT, Tan KL, Yo SL, Hopes E, Harrison TJ, Zuckerman AJ. Molecular epidemiology of hepatitis B virus vaccine variants in Singapore. Vaccine. 1995;13(8):699–702. doi:10.1016/0264-410x(94)00080-7.
   PubMed Web of Science ®Google Scholar
• Chen HL, Lin LH, Hu FC, Lee JT, Lin WT, Yang YJ, Huang FC, Wu SF, Chen SC, Wen WH, et al. Effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV. Gastroenterology. 2012;142(4): 773–81.e2. doi:10.1053/j.gastro.2011.12.035.
   PubMed Web of Science ®Google Scholar
• Wen WH, Huang CW, Chie WC, Yeung CY, Zhao LL, Lin WT, Wu JF, Ni YH, Hsu HY, Chang MH, et al. Quantitative maternal hepatitis B surface antigen predicts maternally transmitted hepatitis B virus infection. Hepatology. 2016;64(5): 1451–61. doi:10.1002/hep.28589.
   PubMed Web of Science ®Google Scholar
• Yin Y, Wu L, Zhang J, Zhou J, Zhang P, Hou H. Identification of risk factors associated with immunoprophylaxis failure to prevent the vertical transmission of hepatitis B virus. J Infect. 2013;66(5):447–52. doi:10.1016/j.jinf.2012.12.008.
   PubMed Web of Science ®Google Scholar
• Zhang L, Gui X, Fan J, Wang B, Ji H, Yisilafu R, Li F, Zhou Y, Tong Y, Kong X, et al. Breast feeding and immunoprophylaxis efficacy of mother-to-child transmission of hepatitis B virus. J Matern Fetal Neonatal Med. 2014;27(2): 182–86. doi:10.3109/14767058.2013.806901.
   PubMed Web of Science ®Google Scholar
• Wang C, Wang C, Jia ZF, Wu X, Wen SM, Kong F, Hu KQ, Li J, Jiang J, Niu JQ. Protective effect of an improved immunization practice of mother-to-infant transmission of hepatitis B virus and risk factors associated with immunoprophylaxis failure. Medicine. 2016;95(34):e4390. doi:10.1097/MD.0000000000004390.
   PubMed Web of Science ®Google Scholar
• Lu Y, Zhu FC, Liu JX, Zhai XJ, Chang ZJ, Yan L, Wei KP, Zhang X, Zhuang H, Li J. The maternal viral threshold for antiviral prophylaxis of perinatal hepatitis B virus transmission in settings with limited resources: a large prospective cohort study in China. Vaccine. 2017;35(48Pt B):6627–33. doi:10.1016/j.vaccine.2017.10.032.
   PubMed Web of Science ®Google Scholar
• Liu J, Xu B, Chen T, Chen J, Feng J, Xu C, Liu L, Hu Y, Zhou YH. Presence of hepatitis B virus markers in umbilical cord blood: exposure to or infection with the virus? Dig Liver Dis. 2019;51(6):864–69. doi:10.1016/j.dld.2018.11.003.
   PubMedGoogle Scholar
• Cheung KW, Seto MTY, Kan ASY, Wong D, Kou KO, So PL, Lau WL, Jalal K, Chee YY, Wong RMS, et al. Immunoprophylaxis failure of infants born to hepatitis B carrier mothers following routine vaccination. Clin Gastroenterol Hepatol. 2018;16(1): 144–45. doi:10.1016/j.cgh.2017.07.013.
   PubMed Web of Science ®Google Scholar
• Kubo A, Shlager L, Marks AR, Lakritz D, Beaumont C, Gabellini K, Corley DA. Prevention of vertical transmission of hepatitis B: an observational study. Ann Intern Med. 2014;160(12):828–35. doi:10.7326/M13-2529.
   PubMed Web of Science ®Google Scholar
• Schillie S, Walker T, Veselsky S, Crowley S, Dusek C, Lazaroff J, Morris SA, Onye K, Ko S, Fenlon N, et al. Outcomes of infants born to women infected with hepatitis B. Pediatrics. 2015;135(5): e1141–7. doi:10.1542/peds.2014-3213.
   PubMed Web of Science ®Google Scholar
• Jourdain G, Ngo-Giang-Huong N, Harrison L, Decker L, Khamduang W, Tierney C, Salvadori N, Cressey TR, Sirirungsi W, Achalapong J, et al. Tenofovir versus placebo to prevent perinatal transmission of hepatitis B. N Engl J Med. 2018;378(10): 911–23. doi:10.1056/NEJMoa1708131.
   PubMed Web of Science ®Google Scholar
• Hu Y, Xu C, Xu B, Hu L, Liu Q, Chen J, Liu J, Liu L, Yang J, Chen T, et al. Safety and efficacy of telbivudine in late pregnancy to prevent mother-to-child transmission of hepatitis B virus: a multicenter prospective cohort study. J Viral Hepat. 2018;25(4): 429–37. doi:10.1111/jvh.12834.
   PubMed Web of Science ®Google Scholar
• Milne A, West DJ, Chinh DV, Moyes CD, Poerschke G. Field evaluation of the efficacy and immunogenicity of recombinant hepatitis B vaccine without HBIG in newborn Vietnamese infants. J Med Virol. 2002;67(3):327–33. doi:10.1002/jmv.10071.
   PubMed Web of Science ®Google Scholar
• Yang YJ, Liu CC, Chen TJ, Lee MF, Chen SH, Shih HH, Chang MH. Role of hepatitis B immunoglobulin in infants born to hepatitis B e antigen-negative carrier mothers in Taiwan. Pediatr Infect Dis J. 2003;22(7):584–88. doi:10.1097/01.inf.0000073123.93220.a8.
   PubMed Web of Science ®Google Scholar
• Lu Y, Liang XF, Wang FZ, Yan L, Li RC, Li YP, Zhu FC, Zhai XJ, Li J, Zhuang H. Hepatitis B vaccine alone may be enough for preventing hepatitis B virus transmission in neonates of HBsAg(+)/HBeAg(-) mothers. Vaccine. 2017;35(1):40–45. doi:10.1016/j.vaccine.2016.11.061.
   PubMed Web of Science ®Google Scholar
• Wang F, Zheng H, Zhang G, Ding Z, Li F, Zhong G, Chen Y, Jia Y, Miao N, Wu Z, et al. Effectiveness of prevention of mother-to-child transmission practice in three provinces of Southern China. Hum Vaccin Immunother. 2015;11(8): 2061–67. doi:10.1080/21645515.2015.1023972.
   PubMed Web of Science ®Google Scholar
• Xu B, Liu L, Yang J. Combined prophylaxis is still better than vaccine only in children of HBV-infected mothers with negative HBeAg. Gastroenterology. 2012;143(1):e42–3. doi:10.1053/j.gastro.2012.04.044.
   PubMed Web of Science ®Google Scholar
• Wiesen E, Diorditsa S, Li X. Progress towards hepatitis B prevention through vaccination in the Western Pacific, 1990–2014. Vaccine. 2016;34(25):2855–62. doi:10.1016/j.vaccine.2016.03.060.
   PubMed Web of Science ®Google Scholar
• Just M, Berger R. Immunogenicity of a heat-treated recombinant DNA hepatitis B vaccine. Vaccine. 1988;6(5):399–400. doi:10.1016/0264-410x(88)90137-5.
   PubMed Web of Science ®Google Scholar
• Van Damme P1, Cramm M, Safary A, Vandepapelière P, Meheus A. Heat stability of a recombinant DNA hepatitis B vaccine. Vaccine. 1992;10(6):366–67. doi:10.1016/0264-410x(92)90064-q.
   PubMed Web of Science ®Google Scholar
• Stephenne J. Development and production aspects of a recombinant yeast-derived hepatitis B vaccine. Vaccine. 1990;8(Suppl):S69–73. doi:10.1016/0264-410x(90)90221-7.
   PubMedGoogle Scholar
• Braun LJ, Jezek J, Peterson S, Tyagi A, Perkins S, Sylvester D, Guy M, Lal M, Priddy S, Plzak H, et al. Characterization of a thermostable hepatitis B vaccine formulation. Vaccine. 2009;27(34): 4609–14. doi:10.1016/j.vaccine.2009.05.069.
   PubMed Web of Science ®Google Scholar
• Otto BF, Suarnawa IM, Stewart T, Nelson C, Ruff TA, Widjaya A, Maynard JE. At-birth immunisation against hepatitis B using a novel pre-filled immunisation device stored outside the cold chain. Vaccine. 1999;18(5–6):498–502. doi:10.1016/s0264-410x(99)00242-x.
   PubMed Web of Science ®Google Scholar
• Hipgrave DB, Maynard JE, Biggs BA. Improving birth dose coverage of hepatitis B vaccine. Bull World Health Organ. 2006;84(1):65–71. doi:10.2471/blt.04.017426.
   PubMed Web of Science ®Google Scholar
• Breakwell L, Anga J, Dadari I, Sadr-Azodi N, Ogaoga D, Patel M. Evaluation of storing hepatitis B vaccine outside the cold chain in the Solomon Islands: identifying opportunities and barriers to implementation. Vaccine. 2017;35(21):2770–74. doi:10.1016/j.vaccine.2017.04.011.
   PubMed Web of Science ®Google Scholar
• Harpaz R, McMahon BJ, Margolis HS, Shapiro CN, Havron D, Carpenter G, Bulkow LR, Wainwright RB. Elimination of new chronic hepatitis B virus infections: results of the Alaska immunization program. J Infect Dis. 2000;181(2):413–18. doi:10.1086/315259.
   PubMed Web of Science ®Google Scholar
• Lin AW, Wong KH. Surveillance and response of hepatitis B virus in Hong Kong special administrative region, 1988–2014. Western Pac Surveill Response J. 2016;7(1):24–28. doi:10.5365/WPSAR.2015.6.3.003.
   PubMedGoogle Scholar
• Miao N, Zheng H, Sun X, Shen L, Wang F, Cui F, Yin Z, Zhang G, Wang F. Enhanced sentinel surveillance for hepatitis B infection in 200 counties in China, 2013–2016. PLoS One. 2019;14(4):e0215580. doi:10.1371/journal.pone.0215580.
   PubMed Web of Science ®Google Scholar
• Cui F, Shen L, Li L, Wang H, Wang F, Bi S, Liu J, Zhang G, Wang F, Zheng H, et al. Prevention of chronic hepatitis B after 3 decades of escalating vaccination policy, China. Emerg Infect Dis. 2017;23(5): 765–72. doi:10.3201/eid2305.161477.
   PubMed Web of Science ®Google Scholar
• Peach D, McMahon BJ, Bulkow L, Funk E, Harpaz R, Margolis HS. Impact of recurrent epidemics of hepatitis a virus infection on population immunity levels: Bristol Bay, Alaska. J Infect Dis. 2002;186(8):1081–85. doi:10.1086/343815.
   PubMed Web of Science ®Google Scholar
• Ni YH, Chang MH, Jan CF, Hsu HY, Chen HL, Wu JF, Chen DS. Continuing decrease in hepatitis B virus infection 30 years after initiation of infant vaccination program in Taiwan. Clin Gastroenterol Hepatol. 2016;14(9):1324–30. doi:10.1016/j.cgh.2016.04.030.
   PubMed Web of Science ®Google Scholar
• Ang LW, Tey SH, Cutter J, James L, Goh KT. Seroprevalence of hepatitis B virus infection among children and adolescents in Singapore, 2008–2010. J Med Virol. 2013;85(4):583–88. doi:10.1002/jmv.23496.
   PubMed Web of Science ®Google Scholar
• Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, Zhang Y, Liu J, Gong X, Chen Y, et al. Epidemiological serosurvey of hepatitis B in China–declining HBV prevalence due to hepatitis B vaccination. Vaccine. 2009;27(47): 6550–57. doi:10.1016/j.vaccine.2009.08.048.
   PubMed Web of Science ®Google Scholar
• Lin X, Yang J, Lu H, Zhou Y, Zhou G, Wu H, Xu C, Wu Q, Liu J, Chen S, et al. Minimization of hepatitis B infection among children in Jiangsu, China, 12 years after integration of hepatitis B vaccine into the expanded program on immunization. Vaccine. 2016;34(51): 6458–63. doi:10.1016/j.vaccine.2016.11.022.
   PubMed Web of Science ®Google Scholar
• Hu Y, Zhang S, Luo C, Liu Q, Zhou YH. Gaps in the prevention of perinatal transmission of hepatitis B virus between recommendations and routine practices in a highly endemic region: a provincial population-based study in China. BMC Infect Dis. 2012;12: 221. doi:10.1186/1471-2334-12-221.
   PubMed Web of Science ®Google Scholar
• Patel MK, Le Calvez E, Wannemuehler K, Ségalin JM. Hepatitis B vaccination coverage and prevalence of hepatitis B surface antigen among children in French Polynesia, 2014. Am J Trop Med Hyg. 2016;94(6):1370–75. doi:10.4269/ajtmh.15-0903.
   PubMed Web of Science ®Google Scholar
• Ang LW, Cutter J, James L, Goh KT. Seroepidemiology of hepatitis B virus infection among adults in Singapore: a 12-year review. Vaccine. 2013;32(1):103–10. doi:10.1016/j.vaccine.2013.10.057.
   PubMed Web of Science ®Google Scholar
• Lao TT, Sahota DS, Chan PKS. Three decades of neonatal vaccination has greatly reduced antenatal prevalence of hepatitis B virus infection among gravidae covered by the program. J Infect. 2018;76(6):543–49. doi:10.1016/j.jinf.2018.04.003.
   PubMed Web of Science ®Google Scholar
• Xu C, Chen T. Global prevalence of hepatitis B virus infection and prevention of mother-to-child transmission. Lancet Gastroenterol Hepatol. 2018;3(9):598–99. doi:10.1016/S2468-1253(18)30198-5.
   PubMed Web of Science ®Google Scholar
• Chang MH, Shau WY, Chen CJ, Wu TC, Kong MS, Liang DC, Hsu HM, Chen HL, Hsu HY, Chen DS. Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls. JAMA. 2000;284(23):3040–42. doi:10.1001/jama.284.23.3040.
   PubMed Web of Science ®Google Scholar
• Chien YC, Jan CF, Chiang CJ, Kuo HS, You SL, Chen CJ. Incomplete hepatitis B immunization, maternal carrier status, and increased risk of liver diseases: a 20-year cohort study of 3.8 million vaccinees. Hepatology. 2014;60(1):125–32. doi:10.1002/hep.27048.
   PubMed Web of Science ®Google Scholar
• Chang MH, You SL, Chen CJ, Liu CJ, Lai MW, Wu TC, Wu SF, Lee CM, Yang SS, Chu HC, et al. Long-term effects of hepatitis B immunization of infants in preventing liver cancer. Gastroenterology. 2016;151(3): 472–80. doi:10.1053/j.gastro.2016.05.048.
   PubMed Web of Science ®Google Scholar
• McMahon BJ, Bulkow LR, Singleton RJ, Williams J, Snowball M, Homan C, Parkinson AJ. Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch-up immunization program. Hepatology. 2011;54(3):801–07. doi:10.1002/hep.24442.
   PubMed Web of Science ®Google Scholar
• Ramírez-Soto MC, Ortega-Cáceres G, Cabezas C. Trends in mortality burden of hepatocellular carcinoma, cirrhosis, and fulminant hepatitis before and after roll-out of the first pilot vaccination program against hepatitis B in Peru: an analysis of death certificate data. Vaccine. 2017;35(31):3808–12. doi:10.1016/j.vaccine.2017.05.086.
   PubMed Web of Science ®Google Scholar